Chinese Expert Consensus Recommendations for the Administration of Immune Checkpoint Inhibitors to Special Cancer Patient Populations
Jun Wang,Bicheng Zhang,Ling Peng,Xiufeng Liu,Jianguo Sun,Chunxia Su,Huijuan Wang,Zheng Zhao,Lu Si,Jianchun Duan,Hongmei Zhang,Mengxia Li,Bo Zhu,Li Zhang,Jin Li,Jun Guo,Rongcheng Luo,Wensheng Qiu,Dingwei Ye,Qian Chu,Jiuwei Cui,Xiaorong Dong,Yun Fan,Quanli Gao,Ye Guo,Zhiyong He,Wenfeng Li,Gen Lin,Lian Liu,Yutao Liu,Haifeng Qin,Shengxiang Ren,Xiubao Ren,Yongsheng Wang,Junli Xue,Yunpeng Yang,Zhenzhou Yang,Lu Yue,Xianbao Zhan,Junping Zhang,Jun Ma,Shukui Qin,Baocheng Wang
DOI: https://doi.org/10.1177/17588359231187205
2023-01-01
Therapeutic Advances in Medical Oncology
Abstract:Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly durable clinical benefits and tolerable toxicities and have improved the survival of patients with various types of cancer. Since 2018, the National Medical Products Administration of China has approved 17 ICIs as the standard treatment for certain advanced or metastatic solid tumors. As ICIs represent a broad-spectrum antitumor strategy, the populations eligible for cancer immunotherapy are rapidly expanding. However, the clinical applications of ICIs in cancer patient populations with special issues, a term that refers to complex subgroups of patients with comorbidities, special clinical conditions, or concomitant medications who are routinely excluded from prospective clinical trials of ICIs or are underrepresented in these trials, represent a great real-world challenge. Although the Chinese Society of Clinical Oncology (CSCO) has provided recommendations for screening before the use of ICIs in special populations, the recommendations for full-course management remain insufficient. The CSCO Expert Committee on Immunotherapy organized leading medical oncology and multidisciplinary experts to develop a consensus that will serve as an important reference for clinicians to guide the proper application of ICIs in special patient populations. This article is a translation of a study first published in Chinese in The Chinese Clinical Oncology (ISSN 1009-0460, CN 32-1577/R) in May 2022 (27(5):442–454). The publisher of the original paper has provided written confirmation of permission to publish this translation in Therapeutic Advances in Medical Oncology.